^
    Back
    Association details:
    Biomarker:IDH2 mutation
    Cancer:Chronic Myelomonocytic Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2020
    Title:

    2189 Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation

    Published date:
    11/04/2020
    Excerpt:
    We retrospectively reviewed pts with CMML, both with and without BT, treated with VEN-based therapy…Two pts had IDH mutations and both achieved CR.
    Secondary therapy:
    Chemotherapy; Hypomethylating agent